Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.

Christina Charles-Schoeman Jon T Giles Nancy E Lane Ernest H S Choy Daniel E Furst Jiri Vencovsky Anthony G Wilson Gerd-Rüdiger R BurmesterDerek CoombsSara K PennNasser KhanJillian B YeeKassim RahawiIain B McInnes

Published in: Rheumatology and therapy (2024)

The results of this integrated long-term analysis of laboratory parameters continue to support an acceptable safety profile of UPA 15 mg QD for moderate-to-severe RA.

Keyphrases

rheumatoid arthritis
disease activity
ankylosing spondylitis
early onset
high intensity
big data
systemic lupus erythematosus
drug induced
machine learning
artificial intelligence
data analysis